| abstract |
This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG72) of human origin. These antibodies have (1) high affinity animal V H and V L sequences which mediate TAG-72 binding and (2) human C H and C L regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human C H and C L antibody domains. The nucleotide and amino acid sequences of V H.alpha.TAG V H, CC46 V H, CC49H, CC83 V H, and CC92 V H, and CC49L, CC83 V L, and CC92 V L idiotype sequences are disclosed, as well as in vivo methods of treatment and diagnostic assay using these chimeric antibodies. |